Exenatide vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | Exenatide | Gonadorelin |
|---|---|---|
| Mechanism | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |